LB 100

Drug Profile

LB 100

Alternative Names: LB-1; LB-100

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer INSERM; Lixte Biotechnology Holdings
  • Class Anti-ischaemics; Antidepressants; Antineoplastics; Small molecules
  • Mechanism of Action Phosphoprotein phosphatase inhibitors; Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Depressive disorders; Glioblastoma; Haematological disorders
  • Research Ischaemia

Most Recent Events

  • 09 Oct 2018 Lixte Biotechnology Holdings files an IND application with the US FDA for phase Ib/II trial in USA for Myelodysplastic syndrome
  • 09 Oct 2018 Lixte Biotechnology Holdings plans a phase Ib/II trial for Myelodysplastic syndrome in USA
  • 24 Aug 2018 Lixte Biotechnology collaborates with Moffitt Cancer Center to initiate phase Ib/II trial of LB 100 in Myelodysplastic syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top